



*vaccines*



an Open Access Journal by MDPI

## Vaccination Strategies for COVID-19 II

Guest Editor:

**Prof. Dr. Martin H. Bluth**

1. Blood Transfusion and Donor Services, Maimonides Medical Center, Brooklyn, NY, USA

2. Department of Pathology, Wayne State University School of Medicine, Detroit, MI, USA

Deadline for manuscript submissions:

**closed (20 January 2024)**

### Message from the Guest Editor

This Special Issue is a continuation of our previous Special Issue, entitled "Vaccination Strategies for COVID-19" ([https://www.mdpi.com/journal/vaccines/special\\_issues/COVID-19\\_vaccine](https://www.mdpi.com/journal/vaccines/special_issues/COVID-19_vaccine)).

We are at the precipice of unprecedented developments in the arena of vaccine development and application. In the wake of COVID-19, government, academia, medicine, science, and engineering have coordinated, matured, and promoted worldwide vaccination strategies as part of the healthcare armamentarium towards curtailing and hopefully eradicating this global pandemic. These include both "tried and true" as well as novel modalities to stimulate the immune system to provide appropriate and hopefully long-lasting protection against the COVID-19 wild-type virus as well as potential variants. In this Special Issue, we entreat those invested in the unique field of vaccine development, application, and the greater healthcare industry to share their understanding with their clinical, scientific, academic, medical, and healthcare colleagues. This will provide a platform to amalgamate efforts and understanding as well as synergize efforts for current and future vaccine initiatives.



[mdpi.com/si/156965](https://mdpi.com/si/156965)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)